6-(3,4-dihydro-3-methyl-2-oxoquinazolinyl)-4,5-dihydro-3-pyridazinone,
6-(6-(3,4-dihydro-3-methyl-2(1H)-2-oxoquinazolinyl))-4,5-dihydro-3(2H)-pyridazinone,
6-DMODP,
prinoxodan,
RG W-2938,
RGW 2938,
RGW-2938,
PRINOXODAN,
111786-07-3,
Prinoxodan [USAN:INN],
Prinoxodanum [INN-Latin],
UNII-W4VMH2E80M,
Prinoxodano [INN-Spanish],
RGW-2938,
RGW 2938,
W4VMH2E80M,
C13H14N4O2,
2(1H)-Quinazolinone, 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-,
3,4-Dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1H)-quinazolinone,
Prinoxodano,
Prinoxodanum,
AC1NSFYF,
Prinoxodan (USAN/INN),
SCHEMBL122042,
CHEMBL2105205,
DTXSID10149732,
WHR-2938,
ZINC5700104,
HY-U00208,
CS-7332,
S066,
LS-140778,
D05612,
3-methyl-6-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-1,4-dihydroquinazolin-2-one,
D08LHE,
C13-H14-N4-O2,
CID5362397,
RG-2938,
3-methyl-6-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-1,4-dihydro,